⌛ Did you miss ProPicks’ 13% gains in May? Subscribe now & catch June’s top AI-picked stocks early.Unlock Stocks

Novo Nordisk stock down as Ozempic trial data misses analyst estimates

Published 05/03/2024, 12:46
© Reuters.

Shares of Novo Nordisk (NYSE:NVO) fell 1.6% in premarket trading Tuesday after the drugmaker released kidney disease trial results that didn't meet investor expectations, Morgan Stanley analysts point out.

A large late-phase trial revealed that Novo Nordisk’s treatment, Ozempic, can reduce the risk of major cardiac arrest and death by 24%, missing the expected benefit of at least 30%, analysts said in a note.

Meanwhile, Jefferies analysts said the detailed data from the trial is “encouraging,” though “perhaps shy of bullish expectations.”

It's reported that approximately 40% of individuals with type 2 diabetes suffer from chronic kidney disease, affecting around 700 million patients worldwide.

Still, the findings from the trial called FLOW serve as further evidence that GLP-1 class medications offer therapeutic advantages for ailments other than their original targets of type 2 diabetes and weight management.

The study, which commenced in 2019, included about 3,500 participants with type 2 diabetes and chronic kidney disease ranging from moderate to severe. These patients received a weekly dose of 1 milligram (mg) of semaglutide alongside their regular treatment.

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.